1046832-21-6

Basic information

• Product Name: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester
• Synonyms: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester;1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1,3-DiMethyl-1H-pyrazol-4-ylboronic acid,pinacol ester;1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 2-(1,3-Dimethyl-1H-pyrazol-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;1,3-DiMethylpyrazole-4-boronic acid pinacol ester;1,3-diMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyrazole;1,3-dimethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1,3-Dimethylpyrazole-4-boronic acid pinacol ester 97%
• CAS NO: 1046832-21-6
• Molecular Formula: C₁₁H₁₉BN₂O₂
• Molecular Weight: 222.09
• Mol File: 1046832-21-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 73.0 to 77.0 °C
• Boiling Point: 322.3±30.0 °C(Predicted)
• Appearance: /
• Density: 1.04±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.56±0.10(Predicted)
• CAS DataBase Reference: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(1046832-21-6)
• EPA Substance Registry System: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(1046832-21-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 1046832-21-6(Hazardous Substances Data)

Usage

Uses

1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester

Upstream product

• 936250-20-3 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 74-88-4 methyl iodide 
• 5775-82-6 4-bromo-1,3-dimethyl-1H-pyrazole 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 73183-34-3 bis(pinacol)diborane 
• 694-48-4 1,3-dimethyl-1H-pyrazole 

Downstream Products

• 1239717-41-9 C₂₇H₂₇N₅O₂ 
• 1558007-83-2 5-(1,3-dimethyl-1H-pyrazol-4-yl)-3-{(1R)-1-[5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-2-amine 
• 1616388-16-9 N-[1-(benzenesulfonyl)-2-(1,3-dimethylpyrazol-4-yl)pyrrolo[2,3-b]pyridin-5-yl]-4,5-dimethyl-1H-pyrazole-3-carboxamide 
• 1612891-16-3 (R)-methyl 2-(1-((2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)oxy)ethyl)-4-fluorobenzoate 
• 1612891-17-4 (R)-2-(1-((2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)oxy)ethyl)-4-fluorobenzoic acid 
• 1612891-05-0 2-[(1R)-1-{[2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl]oxy}ethyl]-4-fluoro-N-methylbenzamide 
• 1612891-07-2 2-[(1R)-1-{[2-amino-5-(1,3-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl]oxy}ethyl]-4-fluoro-N,N-dimethylbenzamide 

Relevant articles and documents

Substituted heteroaryl compound and composition and application thereof

The invention provides a substituted heteroaryl compound and a pharmaceutical composition and application thereof. The compound is a compound as shown in formula (I) or the stereisomer, tautomer, nitric oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in formula (I). The pharmaceutical composition containing the compound can regulate the activity ofprotein kinase and especially the activity of Aurora kinase and JAK kinase and is used for preventing, treating and relieving diseases or disorder mediated by protein kinase and especially JAK kinase.

NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

The present invention embodiments relate to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates in certain embodiments to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates in certain embodiments to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates in certain embodiments to a process for manufacturing compounds of Formula I.

CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION

Compounds of formula (I) and pharmaceutical compositions thereof: wherein A1 A2 and A3 are each independently selected from the group consisting of N and CR3, wherein R1 is an optionally substituted heterocyclyl or an optionally substituted -(C1-6)alkyl-heterocyclyl, R2 is an optionally substituted aryl or an optionally subsisted heteroaryl, R4 is an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inbitor of HIV replication.